Skip to main content

Table 2 Summary of meta-analysis of safety outcomes

From: Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies

Outcome

Studies

Participants

Statistical method

Effect estimate

P-value

I2(%)

Evidence quality

Serious adverse event

2 [22,25]

92

Odd ratio (M-H, Fixed, 95% CI)

0.894 [0.102, 7.808]

0.919

0

Low

Treatment discontinuation due to adverse event

2 [22,25]

92

Odd ratio (M-H, Fixed, 95% CI)

4.288 [0.539, 34.141]

0.169

34.2

Moderate